Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

Acquisition-hungry drug maker Valeant Pharmaceuticals has Allergan in its sights.

Ryan Remiorz/The Canadian Press

Valeant Pharmaceutical International Inc.'s $48-billion (U.S.) hostile bid for Allergan Inc., which has stalled while the target company looks for a white knight, may have to be goosed up to get the deal done.

That's the view of many analysts watching the manoeuvres and they add that Montreal-based Valeant can afford to boost its offer to get a reluctant Allergan on side.

Valeant unveiled its cash and share offer for the California biotech firm, best known for its Botox product line, a week ago. Valeant is making the bid with the assistance of hedge fund manager Bill Ackman, who has accumulated almost 10 per cent of Allergan shares.

Story continues below advertisement

Allergan has said little, except that it will carefully review the proposal. It has put in a place a "poison pill" defence to give it time to look for alternatives.

Bloomberg reported Tuesday that Allergan has contacted a number of companies, including French health-care giant Sanofi SA and American pharmaceutical and packaged goods powerhouse Johnson & Johnson, to see if they are interested in a combination.

And reports out of Europe have suggested Allergan might make its own takeover offer for Irish-based drug maker Shire PLC, creating a low-tax giant that would be too big for Valeant to swallow.

Despite all those possible scenarios Valeant's eventual takeover of Allergan – but at a somewhat higher price – is still seen as the most likely outcome by many of the analysts who cover the two companies.

After an analysts' meeting with Valeant management last Friday, Canaccord Genuity's Neil Maruoka said that "there appears to be a willingness on [Valeant] CEO Mike Pearson's part to provide a higher cash component" in its offer. He concluded that "a higher premium may be required for Valeant to close this transaction."

Sterne Agee's Shibani Malhotra said bluntly that "we expect [Valeant] to increase its bid," and noted that the company has indicated to him that it is "both willing and able" to do so.

Paradigm Capital Inc.'s Alan Ridgeway said he thinks that if there is a competing bid, Valeant could come up with $20 a share more – on top of the current cash and share offer of about $159 per share – and still generate a substantial boost to the combined company's bottom line in the first year through cost savings.

Story continues below advertisement

Those potential savings – Valeant pegs them as high as $2.7-billion in the first year – have become a major point of contention between the two companies.

In their initial presentation about the proposed merger last Tuesday, both Mr. Pearson and Mr. Ackman claimed that Allergan is a bloated company, with a high level of expenses and far to much spending on research and development.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies